Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05898464
PHASE4

Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

Sponsor: Seoul National University Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2023-06-27

Completion Date

2026-03-31

Last Updated

2025-10-02

Healthy Volunteers

No

Interventions

BIOLOGICAL

Recombinant zoster vaccination

Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart

Locations (2)

Seoul National University Hospital

Seoul, South Korea

National Medical Center

Seoul, South Korea